Goshi Ishihara

Title: Goshi Ishihara: Innovator in Cancer Therapy Prediction

Introduction

Goshi Ishihara is a notable inventor based in Yokohama, Japan. He has made significant contributions to the field of cancer therapy through his innovative methods. His work focuses on predicting the efficacy of anti-PD-1 and anti-PD-L1 antibody therapies, which are crucial in the treatment of various cancers.

Latest Patents

Goshi Ishihara holds a patent for a method that predicts the efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy. This method involves measuring the expression level of LAT1 in cancer tissue samples. By assessing the LAT1 expression, the method can predict how a subject will respond to these therapies. Additionally, he has developed a method for evaluating cancer grade, which includes staining cancer tissue samples with anti-LAT1 and anti-PD-L1 antibodies. This evaluation helps determine the malignancy of cancer based on the presence of LAT1-positive and PD-L1-positive sites.

Career Highlights

Throughout his career, Goshi Ishihara has worked with reputable organizations, including J-Pharma Co., Ltd. and Gunma University. His experience in these institutions has allowed him to advance his research and contribute to the development of effective cancer therapies.

Collaborations

Goshi Ishihara has collaborated with notable colleagues, including Hitoshi Endou and Kyoichi Kaira. Their joint efforts have furthered the understanding and application of his innovative methods in cancer treatment.

Conclusion

Goshi Ishihara's contributions to cancer therapy prediction highlight his role as an influential inventor in the medical field. His patented methods offer promising advancements in evaluating and enhancing cancer treatment efficacy.